Eli Lilly has announced encouraging results from its late-stage Phase 3 clinical trial of retatrutide, an investigational next-generation obesity treatment that delivered dramatic weight reduction in adults living with obesity or overweight conditions.
According to the company, participants receiving the highest 12 mg dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks in the TRIUMPH-1 study. The average weight reduction was reported at nearly 70 pounds, with more than 45% of participants achieving at least 30% weight loss, a level typically associated with bariatric surgery outcomes.
Retatrutide is being developed as a once-weekly injectable therapy and works differently from many currently available obesity medicines. The investigational drug activates three hormone receptors GLP-1, GIP, and glucagon which help regulate appetite, insulin activity, and energy expenditure simultaneously. This “triple agonist” approach is being viewed as a potential advancement in obesity treatment.
The Phase 3 study included adults with obesity or overweight individuals with at least one weight-related health condition, excluding diabetes patients. Researchers observed consistent and clinically meaningful reductions in body weight across multiple dose groups, with the strongest results seen in the 12 mg treatment arm.
Lilly also reported that side effects were mostly gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation, which are commonly seen with incretin-based obesity therapies. Some participants experienced sensory-related side effects such as dysesthesia at higher doses.
The results strengthen Lilly’s growing position in the highly competitive obesity drug market, where treatments such as Wegovy and Zepbound have already transformed obesity management globally. Analysts believe retatrutide could become one of the most powerful anti-obesity medicines currently in development if future studies continue to show similar benefits.
Lilly plans to continue additional late-stage trials evaluating retatrutide in obesity, diabetes, cardiovascular disease, and related metabolic disorders, with regulatory submissions expected in the coming years.
